Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
KURA 
Kura Oncology Inc (KURA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: KURA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
15 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $27
1 Year Target Price $27
| 10 | Strong Buy |
| 3 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 24.7% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 700.45M USD | Price to earnings Ratio - | 1Y Target Price 27 |
Price to earnings Ratio - | 1Y Target Price 27 | ||
Volume (30-day avg) 15 | Beta 0.4 | 52 Weeks Range 5.41 - 21.57 | Updated Date 08/29/2025 |
52 Weeks Range 5.41 - 21.57 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.31 |
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.41 | Actual -0.75 |
Profitability
Profit Margin -236.76% | Operating Margin (TTM) -475.31% |
Management Effectiveness
Return on Assets (TTM) -22.93% | Return on Equity (TTM) -51.11% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 89198282 | Price to Sales(TTM) 8.41 |
Enterprise Value 89198282 | Price to Sales(TTM) 8.41 | ||
Enterprise Value to Revenue 1.07 | Enterprise Value to EBITDA -2.48 | Shares Outstanding 86797200 | Shares Floating 63986017 |
Shares Outstanding 86797200 | Shares Floating 63986017 | ||
Percent Insiders 1.15 | Percent Institutions 95.88 |
Upturn AI SWOT
Kura Oncology Inc
Company Overview
History and Background
Kura Oncology Inc. is a biopharmaceutical company focused on developing and commercializing precision medicines for the treatment of cancer. Founded in 2014, Kura has advanced a pipeline of drug candidates targeting cancer signaling pathways.
Core Business Areas
- Drug Development: Kura Oncology focuses on researching and developing small molecule drug candidates that target key signaling pathways involved in cancer growth and survival.
Leadership and Structure
Troy Wilson is the President and Chief Executive Officer. The company has a typical organizational structure with departments such as research and development, clinical operations, regulatory affairs, and finance.
Top Products and Market Share
Key Offerings
- Tipifarnib (KO-539): An oral, selective inhibitor of farnesyltransferase (FTase). Currently being investigated in clinical trials for relapsed/refractory acute myeloid leukemia (AML) with NPM1 mutations. Competitors include other companies developing therapies for AML.
- Ziftomenib (KO-2806): A novel, potent and selective inhibitor of the enzyme menin. Currently being evaluated in patients with NPM1-mutant AML. Competitors include companies developing therapies for AML or menin inhibitors.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and stringent regulatory requirements. There is a growing focus on precision medicine and targeted therapies.
Positioning
Kura Oncology is focused on developing precision medicines for genetically defined cancers. Its competitive advantage lies in its targeted approach and pipeline of novel drug candidates.
Total Addressable Market (TAM)
The market for targeted cancer therapies is estimated to be worth billions of dollars. Kura Oncology is positioned to capture a share of this market with its pipeline of precision medicines.
Upturn SWOT Analysis
Strengths
- Pipeline of targeted therapies
- Experienced management team
- Focus on genetically defined cancers
- Strong intellectual property position
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- High risk of drug development failure
- Limited commercialization experience
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline
- FDA approval of drug candidates
Threats
- Competition from other pharmaceutical companies
- Regulatory hurdles
- Patent challenges
- Unfavorable clinical trial outcomes
Competitors and Market Share
Key Competitors
- MRTX
- BLU
- GILD
Competitive Landscape
Kura Oncology competes with other biopharmaceutical companies developing targeted cancer therapies. Its competitive advantages include its focus on genetically defined cancers and its pipeline of novel drug candidates. Disadvantages include the limited financial resources and commercialization experience.
Growth Trajectory and Initiatives
Historical Growth: Kura Oncology's growth is dependent on the success of its clinical trials and regulatory approvals.
Future Projections: Future growth projections are based on analyst estimates of potential drug sales and market penetration.
Recent Initiatives: Recent initiatives include advancing clinical trials for tipifarnib and Ziftomenib and exploring new drug targets.
Summary
Kura Oncology is a clinical-stage biopharmaceutical company with a promising pipeline focused on targeted cancer therapies. Its success hinges on the positive outcomes of ongoing clinical trials and securing regulatory approvals. The company faces competition and financial risks, but its focus on precision medicine provides a potential advantage. The lack of a strong financials and being a microcap company pose risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kura Oncology Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2015-09-22 | Chairman, CEO & President Dr. Troy Edward Wilson J.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 192 | Website https://kuraoncology.com |
Full time employees 192 | Website https://kuraoncology.com | ||
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a selective investigational FTI for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies; and a clinical collaboration with Mirati Therapeutics, Inc. to evaluate the combination of KO-2806 and adagrasib, a KRASG12C inhibitor in patients with NSCLC. The company is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.